Syntiron aims to save newborns–too young to be vaccinated–by targeting bacteria that cause common urinary tract infections in pregnant mothers

(BOSTON: January 18, 2024) – Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding Syntiron US$1.7 million to develop a maternal vaccine that targets Escherichia coli and Klebsiella pneumoniae, two bacterial species that cause a large portion of neonatal sepsis infections.  Neonatal sepsis is a life-threatening response to bloodstream infections that occur in newborns fewer than 28 days old. Due to their immature immune systems, newborns are particularly susceptible to infections. The BARNARDS study estimated that 2.5 million neonates or infants in the first month of life die annually of sepsis, with the greatest burden in low- and middle-income countries. Since neonatal sepsis progresses rapidly, it requires immediate treatment with IV fluids and antibiotics. The risk of death from neonatal sepsis increases 7.6% every hour a treatment is delayed.

 “CARB-X is excited to support the development of Syntiron’s maternal vaccine to help prevent neonatal sepsis, the leading cause of death among infants, especially those located in low- and middle-income countries,” said Erin Duffy, PhD, R&D Chief of CARB-X. “Because newborns at risk for neonatal sepsis are too young to be immunized, the vaccine would be administered to expectant mothers and target bacteria that cause neonatal bloodstream infections in babies and urinary tract infections (UTIs) in mothers. The vaccinated mothers would pass antibodies on to their babies in utero and through breastmilk after birth to strengthen their newborns’ immune systems, helping them ward off infections.”

The CARB-X award supports the development of Syntiron’s Alloy-EK vaccine, which leverages iron receptor proteins (IRPs) as vaccine targets. IRPs are highly genetically conserved, which means they are less likely to change since they perform essential functions. This makes them reliable targets. Syntiron developed the Alloy Platform to safely manufacture and formulate IRP vaccines that maintain robust immunity and cover a broad range of bacterial strains.

 “The bacteria targeted by this vaccine are a tremendous burden on public health for babies, children and adults worldwide,” said Lisa Herron-Olson, PhD, Managing Director of Syntiron. “Pregnant women are at particularly high risk of infection by these same bacteria that can cause neonatal sepsis in newborn babies. Preventing these infections by vaccination offers substantial potential health benefit to mothers and babies, while reducing the spread of antimicrobial resistance. The Syntiron team appreciates the support of CARB-X as we bring this vaccine platform forward to improve maternal and infant health throughout the world.”

 An estimated 1.27 million people died due to drug-resistant bacterial infections in 2019, a death toll that exceeded HIV/AIDS (864,000) and malaria (643,000) in that same year. CARB-X is building a pipeline of high-value products to prevent, diagnose and treat the most dangerous bacterial infections that have become resistant to antibiotics. In its first seven years, CARB-X supported 93 R&D projects in 12 countries, and CARB-X product developers have made tremendous progress: 18 projects have advanced into or completed clinical trials; 12 remain active in clinical development, including late-stage clinical trials; and two diagnostic products have reached the market. Additionally, at least 9 product developers with active R&D projects have already secured advanced development partnerships which can help support their clinical development after leaving the CARB-X portfolio.

About Syntiron

Syntiron is developing a portfolio of vaccines to prevent bacterial infections in humans, especially those caused by antimicrobial resistant (AMR) bacteria. Syntiron’s Alloy Vaccine Platform leverages bacterial iron receptor proteins as a blueprint for engineering highly immunogenic and broadly protective vaccines in the form of simple proteins. Iron receptor proteins are critical to bacterial survival, and these proteins are highly conserved among different strains and species of bacteria that cause infections. Alloy Vaccines are engineered for simple production and can achieve superior breadth of coverage relative to traditional vaccines targeting more variable components. The indication for Syntiron’s lead Alloy Vaccine is for urinary tract infection, especially among women and older adults.

About CARB-X

CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. CARB-X supports innovative therapeutics, preventatives and rapid diagnostics. CARB-X is led by Boston University and funded by a consortium of governments and foundations, including Wellcome, HHS/BARDA, Germany’s Federal Ministry of Education and Research (BMBF), the UK Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Bill & Melinda Gates Foundation and the Novo Nordisk Foundation. The U.S. National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH) in HHS, provides support in the form of in-kind services through access to a suite of preclinical services for product develpment. CARB-X funds only projects that target drug-resistant bacteria highlighted on the CDC’s Antibiotic Resistant Threats list, or the Priority Bacterial Pathogens list published by the WHO, with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list. | X (formerly Twitter) @CARB_X

Syntiron actively seeks partnerships that contribute to the advancement of human vaccines. For more information on our project and partnership opportunities, please contact us.


1000 Westgate Drive
St Paul MN 55114